Mark E. Dmytruk - Mar 1, 2023 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role: Chief Financial Officer
Signature: /s/ Karen Tepichin, Attorney-in-Fact
Stock symbol: DNA
Transactions as of: Mar 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/10/2023, 03:16 PM
Previous filing: Feb 3, 2023
Next filing: Mar 16, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNA	Restricted Stock Units	Award		+870K			870K	Mar 1, 2023	Class A Common Stock	870K		Direct	F1, F2
holding	DNA	Restricted Stock Units						1.63M	Mar 1, 2023	Class A Common Stock	1.63M		Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2	The RSUs vest in 48 equal monthly installments beginning on April 1, 2023.
F3	Represents RSUs granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022.

Remarks:

Chief Financial Officer